Olitigaltin (TD-139)

Catalog No.S0471 Batch:S047101

Print

Technical Data

Formula

C28H30F2N6O8S
Molecular Weight 648.64 CAS No. 1450824-22-2
Solubility (25°C)* In vitro DMSO 100 mg/mL (154.16 mM)
Water ˂1 mg/mL
Ethanol ˂1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Olitigaltin (TD-139, GB0-139) is a potent and selective inhibitor of galectin-3 with Kd of 0.036 µM over galectin-1 and galectin-7 with Kd of 2.2 µM and 32 µM, respectively. TD-139 is used potentially for the treatment of idiopathic pulmonary fibrosis (IPF).
Targets
galectin-3 [1]
(Cell-free assay)		 galectin-1 [1]
(Cell-free assay)		 galectin-7 [1]
(Cell-free assay)
0.036 μM(Kd) 2.2 μM(Kd) 32 μM(Kd)
In vitro

In primary lung alveolar epithelial cells (AECs), Olitigaltin (TD-139) which is a novel high-affinity inhibitor of the galectin-3 carbohydrate binding domain, reduces TGF-β1- induced β-catenin translocation to the nucleus, also blocks TGF-β1–induced β-catenin phosphorylation.[2]
In vivo

Olitigaltin (TD-139), a highly potent, selecitve inhibitor of Galectin-3 (Gal-3) carbohydrate, produces a significant decrease in total lung collagen, also decreases β-catenin activation in bleomycin model of pulmonary fibrosis.[2]

Protocol (from reference)

Selleck's Olitigaltin (TD-139) has been cited by 7 publications

In vitro and in vivo effects of Galectin-3 inhibitor TD139 on inflammation and ERK/JNK/p38 pathway in gestational diabetes mellitus [ Kaohsiung J Med Sci, 2024, 40(10):916-925] PubMed: 39230472
Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3 [ Front Immunol, 2023, 14:1286097] PubMed: 38259448
Epithelial Galectin-3 Induced the Mitochondrial Complex Inhibition and Cell Cycle Arrest of CD8+ T Cells in Severe/Critical COVID-19 [ Int J Mol Sci, 2023, 24(16)12780] PubMed: 37628961
Epithelial Galectin-3 Induced the Mitochondrial Complex Inhibition and Cell Cycle Arrest of CD8+ T Cells in Severe/Critical COVID-19 [ Int J Mol Sci, 2023, 24(16)12780] PubMed: 37628961
Inhibition of Galectin-3 in a Rat Model of Epilepsy and Kainate-Activated BV2 Cells Limits Microglial Activation Through the NLRP3/Pyroptosis Pathway [ Neuroimmunomodulation, 2023, 30(1):325-337] PubMed: 37926077
Galectin-3 promotes the adipogenic differentiation of PDGFRα+ cells and ectopic fat formation in regenerating muscle [ Development, 2022, dev.199443] PubMed: 35029658
Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells [ Front Allergy, 2022, 3:840454] PubMed: 35386657

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.